13C6-Glucose / Metabolism / Glucose · Interventional Study

Tracing Of Real-time glu13Cose Metabolism in Human Immune Cells - Intensive Care Unit

ClinicalTrials.gov · September 9, 2026

Preliminary Why this matters to you Expert discussion

Early or partial results. Treat as a signal, not a conclusion.

AI Summary

This is a registry record for a planned mechanistic study of glucose metabolism in immune cells during critical illness, using 13C-glucose isotope tracing. No results are reported. The study is intended to generate descriptive data on how immune cells metabolize glucose in ICU patients but will not evaluate clinical outcomes or treatment effects.

What was studied

Interventional, Single Group, Open label, Basic Science purpose. Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis; age from 18 Years. Intervention: 13C6-Glucose. n = 25. 1 site: United States.

Key findings

Safety

Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.

Who this may help

The source did not state who this applies to in practice.

Plain-language summary

This is a planned interventional mechanistic study with no results reported; it aims to characterize glucose metabolism in immune cells during critical illness using isotope tracing in a small ICU cohort.

Study design

As stated by the source record.

MethodsPrimary outcome measure: 13C6-Glucose Uptake and Metabolism in Immune Cells (assessed at Up to 4 hours)

DesignInterventional, Single Group, Open label, Basic Science purpose

PopulationGlucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis; age from 18 Years

Sample size25

Intervention13C6-Glucose

Setting1 site: United States

Reported figures

Quoted from the source exactly as published.

Planned enrollment25

Primary outcome measure13C6-Glucose Uptake and Metabolism in Immune Cells, Up to 4 hours

Intervention13C6-Glucose intravenous infusion

Caveats

This is a registry record with no results posted; study recruitment has not yet begun.
No sample size justification, power analysis, or statistical analysis plan is described.
Primary outcome is mechanistic (tracer uptake); no clinical outcomes are reported or planned.
Study phase is listed as 'NA'; blinding, randomization, and comparator arm are not described.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Study design

moderate

Interventional tracer study with defined protocol and primary outcome measure.

Directness

moderate

Mechanistic endpoint (glucose uptake and metabolism) in relevant population (ICU patients).

Consistency

insufficient

No results reported; consistency with prior work cannot be assessed.

Risk of bias

insufficient

Registry record does not describe blinding, allocation concealment, or analytical methods.

Sample adequacy

limited

Planned enrollment 25 participants; mechanistic study, not powered for clinical outcomes.

What is missing. This record has no key findings. That is a gap in the analysis, not a judgement about the study.

Source abstract

Registry record from ClinicalTrials.gov (NCT07811180). This is a study registration, not published results. Lead sponsor: Vanderbilt University Medical Center. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 25 participants (ESTIMATED). Conditions: Glucose, Metabolism, Isotope Labeling, Immune System and Related Disorders, Critical Illness, Intensive Care Unit (ICU), Sepsis. Interventions: DRUG: 13C6-Glucose. Primary outcome measures: 13C6-Glucose Uptake and Metabolism in Immune Cells , Up to 4 hours. Brief summary: The purpose of this study is to understand how cells of the immune system use the common sugar glucose during critical illness. Investigators will intravenously infuse a non-radioactive carbon-13 glucose tracer into adult intensive care unit (ICU) participants over a few hours and collect immune cells from the blood to track uptake and usage of this glucose within these immune cells.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.

NCT0781118013C6-GlucoseMetabolismGlucoseVanderbilt University Medical CenterIsotope Labeling